Navigation Links
VIVUS to Present at Four Upcoming Investor Conferences
Date:9/10/2010

MOUNTAIN VIEW, Calif., Sept. 10 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of September.  The conference presentation schedule is as follows:Bank of America Merrill Lynch Global Healthcare Conference Presented by: Timothy Morris, chief financial officerSeptember 16, 2010 at 2:30 p.m. BST Bank of America Merrill Lynch Financial Centre, London, UKStifel Nicolaus 2010 Healthcare ConferencePresented by: Dr. Wesley Day, vice president, clinical development September 17, 2010 at 9:45 a.m. EDTFour Seasons, Boston, MAUBS Global Life Sciences ConferencePresented by: Timothy Morris, chief financial officerSeptember 22, 2010 at 12:30 p.m. EDTThe Grand Hyatt, New York, NYThe Fifth Annual JMP Securities Healthcare ConferencePresented by: Timothy Morris, chief financial officerSeptember 28, 2010 at 8:30 a.m. EDTThe Palace Hotel, New York, NYA live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information a
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIVUS to Present at Two Upcoming Investor Conferences
2. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
3. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
4. VIVUS to Present at Four Upcoming Healthcare Conferences
5. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
6. VIVUS to Present at the Needham and Company Life Sciences Conference
7. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
8. VIVUS Reports First Quarter 2009 Financial Results and Highlights
9. Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Lexicon to Present at Stifel Nicolaus Healthcare Conference
11. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... hypothermic storage and cryopreservation freeze media and ... ("BioLife" or the "Company"), today announced that it will hold ... (the "Annual Meeting"). Because the expected date for ...
(Date:12/24/2014)... 2014 Earlier this year in a June ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... property of adult tissue stem cells. His title “Asymmetric ... for the Future,” embodied the essence of his message to ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... CHENGDU, China , June 3 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc. (NYSE ... the updated corporate presentation at the Company,s website: , , ... http://www.tianyinpharma.com , , , ... , , ...
... June 2 Caliper Life Sciences, Inc. (Nasdaq: CALP ... Sciences Conference, will be webcast on Friday, June 11 at ... will be providing an update on the company,s business. The live webcast ... available for 90 days. , , ...
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin ... at the Jefferies 2010 Global Life Sciences Conference and also at the 9th ... , , ... place on Wednesday, June 9, 2010 at 1:30 p.m. Eastern ...
Cached Biology Technology:Tianyin Corporate Presentation Updated 2Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference 2
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
(Date:1/22/2015)... 2015   EyeLock, Inc. , a market leader of iris-based ... Gerber to the new role of Senior Vice President ... development of mobile platforms and wearable solutions for EyeLock,s technologies. ... in the semiconductor industry to his role at EyeLock, with ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... great number of women experience depression or anxiety while ... mood disorders may lead to long-term emotional and behavioral ... the fetal environment has a strong influence on offspring ... exact mechanisms by which this occurs are not completely ...
... turns out that your messenger RNA may catch more than one ... mRNA may travel one way down a cell, then board another, ... get where it ultimately needs to be. It,s a ... differentiating a brain cell from, say, a muscle cell, said ...
... genetic material in our cells are iconically depicted as ... cell is about to divide and the entire contents of ... to get a good picture of the way that our ... is neatly bundled into the nucleus while enabling day-to-day (non-dividing) ...
Cached Biology News:2-way traffic enable proteins to get where needed, avoid disease 2Chromosomes show off their shapes 2
Immulon 2 HB 1x8 Strip assembled, C-bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
... RCT series of refrigerated cold traps offers ... of low volatility/aqueous solvents or high volatility ... other vacuum concentrators/centrifugal evaporators. Also used for ... such as used in electron microscopes. Can ...
96 Well Plate UB, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Thermo Forma provides an array of accessory Racks for the Cryo/CryoPlus 16" Diameter storage system. To maximise inventory capacity a Jumbo Arrowhead configuration is recommended. You may choose betw...
Biology Products: